The company will use the proceeds from the round to invest in sales and marketing efforts for its Sapientia clinical genome analysis platform, as well as for R&D.
OncoDNA has launched two new precision cancer medicine projects, the budgets for which total €16 million and are being supported in part by the Belgian Walloon Region.
Multiple molecular disease diagnoses were made in nearly 5 percent of individuals where exome sequencing was informative.
Sophia's platform will be used to analyze data from Devyser's hereditary breast cancer and cystic fibrosis testing kits.
The company's recently launched nucleic acid isolation and purification kit is just one of several new products the company hopes bring to the market over the next few years.
Ambry's new lab provides a streamlined, automated workflow that has allowed the company to triple its daily testing volume since it opened more than four months ago.
The companies will combine MolecularMD's specialty diagnostic assays with Definiens' quantitative tissue read-outs to provide customized diagnostic solutions in oncology.
When molecular testing did affect the surgical plan, it often led to overtreatment, according to the Johns Hopkins University School of Medicine team.
OpGen will add a commercial data visualization portal to its CLIA testing service and launch an integrated product and services offering this year.
Researchers outlined nine regulatory research-related challenges to validating, advancing, and improving next-generation sequencing-based diagnostic tests.
An opinion piece in the New York Times urges lawmakers to keep genetic protections in place.
Research funding in Canada is to remain mostly the same, ScienceInsider reports.
In Science this week: random DNA replication errors play role in cancer, and more.
The Bill and Melinda Gates Foundation embarks on an open-access publishing path.